

THE POWER OF PLUS WITH PURAPLY® AM

Native extracellular matrix scaffold + sustained antimicrobial effectiveness within the product to support wound healing and aid in granulation tissue formation¹⁻⁴



NATIVE, CROSS-LINKED ECM

- Provides a scaffold for cellular migration and proliferation⁵
- Resists protease degradation^{3,6,7}
- Inhibits a wide range of MMPs and controls excess proteases^{3,6,7}



BROAD-SPECTRUM PHMB

- Proactively disrupts bioburden^{1,3,8}
- Exhibits no known bacterial resistance to date^{3,8,9}
- Demonstrates high tissue compatibility and low cytotoxicity^{2,8,9}



| PuraPly® AM

PROVEN REAL-WORLD EFFECTIVENESS

THE STUDY

N=307
28 Sites

Prospective, multicenter cohort study⁴

Large Difficult-to-Heal Wounds

12.9 cm² mean wound area⁴

THE RESULTS

86%

of wounds demonstrated improvement in wound bed conditions⁴



Increased granulation tissue



Reduced exudate



Readiness for other advanced skin substitutes

85%

of wounds achieved >75% reduction in volume⁴

ECM=extracellular matrix; PHMB=polyhexamethylene biguanide


Note: PuraPly AM resists microbial colonization within the product and reduces microbes penetrating through it. PuraPly AM will naturally be resorbed into the wound and is not intended to be removed.¹

SCIENTIFIC EVIDENCE

ANTIMICROBIAL EFFECTIVENESS WITHIN PURAPLY AM^{2,*}

>99%

MRSA reduction from post-debridement baseline




^aP<0.05 vs pre- and post-debridement baseline; ^bP<0.05 vs Aquacel Ag and PriMatrix Ag; ^cP<0.05 vs BlastX; ^dP<0.05 vs pre-debridement baseline

Data shown compared MRSA (methicillin-resistant *Staphylococcus aureus*) colonies in each wound, using a porcine deep reticular dermal wound model

PURAPLY AM LOW CYTOTOXICITY^{2,*}

>94%

Fibroblast viability at 48 hours




^aP<0.001 vs Blast X

Data shown measured cell proliferation and cell viability using human dermal fibroblasts in media conditioned with test materials

¹In a study evaluating the antimicrobial effectiveness within PuraPly AM and PuraPly XT versus a variety of other wound products

PURAPLY® AM HELPS YOU MANAGE WOUNDS FROM HEAD-TO-TOE WITH A WIDE VARIETY OF SIZES¹



*Abrasions, lacerations, second-degree burns, skin tears

[†]Donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence

References: 1. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2023. 2. Davis SC, et al. *Int Wound J*. 2022;19(1):86-99. 3. Brantley J, et al. *Wounds Int*. 2016;7(3):1-5. 4. Bain MA, et al. *J Comp Eff Res*. 2020;9(10):691-703. 5. Data on file. PDR-0008. Organogenesis Inc. 6. Carpenter S, et al. *Wounds*. 2016;28(6 suppl):S1-S20. 7. Data on file. PDR-0005. Organogenesis Inc. 8. Gilbert P, et al. *J Appl Microbiol*. 2005;99(4):703-715. 9. Hübner NO, et al. *Skin Pharmacol Physiol*. 2010;23(1 suppl):17-27.